- Article
- Source: Campus Sanofi
- Jul 9, 2025
Rezurock Economic Value
_430x268.jpg)
.svg)
Rezurock is a cost-effective treatment when compared to the available treatments against 3L cGVHD,with a coverage resulting in a neutral/limited incremental budget impact.1
Cost-effectiveness Analysis1,3
- At a WTP of £30,000 per QALY gained, Belumosudil demonstrated a significant clinical benefit versus BATs with an incremental gain of: 0.854 QALYs
- Belumosudil is cost-effective vs. BAT in patients aged 12 years and older with cGVHD who received at least two prior lines of systemic therapy.
Budget-impact Analysis2
- Costs savings associated with the management of AEs (e.g., neutropenia and thrombocytopenia) in 2026 are projected to be ≈$108.4M
- Costs savings associated with healthcare resources utilization (e.g., emergency room visits, ICU stays) in 2026 are projected to be ≈$65.1M
Belumosudil allows for the offset of healthcare system costs compared with BAT, resulting in a $128.8M cost savings from a national US payer perspective
3L: Third line; WTP: Willingness-to-pay; AE: Adverse event; RWE: Real-world evidence; ICU: Intensive Care Unit; LOT: Line of therapy; BAT: Best available therapies; cGVHD: Chronic graft-versus-host disease; US: United States.
-
Data on file. Data on Sanofi file, mini-CVD, Final Draft_without naïve comparison section_clean.
-
Carlos R. Bachier, Jeffrey R. Skaar, Sumudu Dehipawala, Benjamin Miao, Jonathan Ieyoub & Haya Taitel (2022) budget impact analysis of belumosudil for chronic graft-versus-host disease treatment in the United States, Journal of Medical Economics, DOI: 10.1080/13696998.2022.2087408
-
NICE Guidance: ‘Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over’. Available at: https://www.nice.org.uk/guidance/ta949
MAT-KW-2500349